AbbVie inks Humira patent deal No. 7, delaying Pfizer's U.S. biosim launch until late 2023
admin 30th November 2018 Uncategorised 0Following a handful of deals for other biosimilar drugmakers, Pfizer decided to settle its Humira patent fight with AbbVie and agreed on a Nov. 20, 2023, U.S. launch date for its copy. More: AbbVie inks Humira patent deal No. 7,
read more